TY - JOUR
T1 - Biologic activity of a nucleotide conjugate between mitomycin c and cytarabine monophosphate
AU - Dorr, Robert T.
AU - James, D.
N1 - Funding Information:
Supported in part by grants CA-21430 and CA-17094 from the National Institutes of Health, National Cancer Institute, Bethesda, MD, U.S.A.
PY - 1994/9/1
Y1 - 1994/9/1
N2 - A dual prodrug conjugate between the antimetabolite cytarabine monophosphate and the alkylating agent 2,7-diaminomitosene (derived from mitomycin C), cytaramycin, was synthesized and tested for antileukemic activity in sensitive and resistant tumors. The compound was active against parental L-1210, CCRF-CEM, HL-60 and K-562 leukemia cells but did not overcome resistance in sublines developed for (1) multidrug resistance (L-1210/MDR and K-562-R) or (2) for cytarabine resistance (CCRF-CEM/ARA-C and HL-60/ARA-C). Alkaline DNA elution tests demonstrate a predominance of strand breaking activity due to the cytarabine moiety, and a lesser degree of DNA crosslinking, due to the mitosene moiety. The conjugate was active in mice bearing P-388 leukemia (80% increased lifespan), but was not more effective than mitomycin C alone in mice bearing a cytarabine-resistant L-1210 cell line (38% to 31% increased lifespan). These findings suggest that mitomycin nucleotide conjugates do not overcome resistance to the parent antimetabolites.
AB - A dual prodrug conjugate between the antimetabolite cytarabine monophosphate and the alkylating agent 2,7-diaminomitosene (derived from mitomycin C), cytaramycin, was synthesized and tested for antileukemic activity in sensitive and resistant tumors. The compound was active against parental L-1210, CCRF-CEM, HL-60 and K-562 leukemia cells but did not overcome resistance in sublines developed for (1) multidrug resistance (L-1210/MDR and K-562-R) or (2) for cytarabine resistance (CCRF-CEM/ARA-C and HL-60/ARA-C). Alkaline DNA elution tests demonstrate a predominance of strand breaking activity due to the cytarabine moiety, and a lesser degree of DNA crosslinking, due to the mitosene moiety. The conjugate was active in mice bearing P-388 leukemia (80% increased lifespan), but was not more effective than mitomycin C alone in mice bearing a cytarabine-resistant L-1210 cell line (38% to 31% increased lifespan). These findings suggest that mitomycin nucleotide conjugates do not overcome resistance to the parent antimetabolites.
UR - http://www.scopus.com/inward/record.url?scp=0027933987&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027933987&partnerID=8YFLogxK
U2 - 10.1080/15257779408009471
DO - 10.1080/15257779408009471
M3 - Article
AN - SCOPUS:0027933987
SN - 0732-8311
VL - 13
SP - 1655
EP - 1667
JO - Nucleosides and Nucleotides
JF - Nucleosides and Nucleotides
IS - 8
ER -